About this trial
This study investigates how cocaine use and withdrawal affect sleep and circadian rhythms in individuals undergoing inpatient detoxification. Using wearable sleep monitors, actigraphy, questionnaires, and hormonal biomarkers, it aims to capture both objective and subjective changes in sleep across three key stages: active use, early withdrawal, and late withdrawal. The study is unique in its ability to explore sleep microstructure, the circadian system's role via melatonin and cortisol measurements, and the dynamic relationship between subjective sleep perception and objective sleep data. It also examines whether sleep quality may serve as a predictive marker of long-term withdrawal success.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Male or female, aged 18 years or older
Meeting DSM-5 criteria for cocaine use disorder
Positive urine drug screen for cocaine
Scheduled for inpatient supervised cocaine detoxification within the next four weeks
Disqualifiers
Current diagnosis of opioid use disorder or other psychostimulant use disorders (e.g., amphetamines, methamphetamines, cathinones, methylphenidate)
Unstable psychiatric disorder or somatic illness deemed incompatible with study participation by the investigator
Current treatment with methylphenidate, modafinil, solriamfetol, melatonin, pitolisant, naltrexone, or bupropion
Patients under legal guardianship
Trial population
Patients with cocaine use disorder seeking hospitalization for withdrawal
Trial design
Cohort
Prospective
Treatments tested in this trial
Multimodal Sleep and Biomarker Assessment
Other interventionParticipants will undergo non-invasive sleep assessments including polysomnography recordings (using the Somfit® device), actigraphy, self-reported questionnaires (on sleep, substance use), and urinary biomarker collection (for cortisol and melatonin levels) at three distinct stages of their substance use/withdrawal timeline.
Treatment groups
Trial outcomes
Primary outcomes
Sleep Efficiency (%) measured by polysomnography
Sleep efficiency, defined as the ratio of total sleep time to time spent in bed, will be assessed using the Somfit® wearable device. Measurements will be conducted over three visits corresponding to distinct stages of cocaine use and withdrawal: V1 (active use), V2 (early withdrawal), and V3 (late withdrawal). Each visit includes two consecutive nights of recording, and the 2 nights will be averaged for analysis purposes. This double recording also makes it possible to obtain data from one night if the second encounters a technical problem. The primary outcome will be derived from data collected over a 16-hour window encompassing the nocturnal sleep period.
Secondary outcomes
Objective Sleep Parameters measured by polysomnography
Objective sleep metrics including total sleep time (min), sleep onset latency (min), wake after sleep onset (WASO, min), REM sleep duration and latency, time spent in N1, N2, N3 stages (min and %), micro-arousal index, phasic/tonic REM proportions, spindle index in NREM sleep, and delta power during N3 will be recorded via polysomnography (SOMFIT) across three study visits (each comprising two nights of measurement).
Sleep-Wake Rhythm Parameters from Actigraphy
Actigraphy data from the MotionWatch 8® will be used to assess weekly sleep-wake patterns. Extracted parameters include sleep onset and offset times, sleep midpoint, time in bed, total sleep time, sleep onset latency, WASO, sleep efficiency, and diurnal naps (presence, number, duration, and timing).
Sleep-Wake Rhythm Parameters from Sleep Diary
Entries in the sleep diary will be used to assess weekly sleep-wake patterns
Subjective Sleep Scores
Sleep-related self-reported outcomes will be assessed using the following validated questionnaires completed after polysomnography nights.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.